Lixte Biotechnology (NASDAQ:NMAD) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Lixte Biotechnology (NASDAQ:NMAD) from a hold rating to a sell rating in a report published on Saturday.

Separately, Weiss Ratings lowered shares of Lixte Biotechnology from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Lixte Biotechnology Trading Up 2.1%

NMAD opened at $4.30 on Friday. Lixte Biotechnology has a 12-month low of $2.36 and a 12-month high of $8.38. The firm has a 50 day moving average of $7.10 and a two-hundred day moving average of $5.05. The firm has a market capitalization of $69.23 million, a PE ratio of -4.30 and a beta of 1.29.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Equitable Holdings Inc. purchased a new stake in Lixte Biotechnology in the 2nd quarter worth approximately $74,000. Axxcess Wealth Management LLC acquired a new stake in shares of Lixte Biotechnology during the 4th quarter worth approximately $54,000. XTX Topco Ltd purchased a new position in shares of Lixte Biotechnology during the 4th quarter valued at approximately $57,000. FNY Investment Advisers LLC purchased a new position in shares of Lixte Biotechnology during the 2nd quarter valued at approximately $330,000. Finally, Geode Capital Management LLC lifted its stake in shares of Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after purchasing an additional 10,722 shares during the period. 5.10% of the stock is currently owned by hedge funds and other institutional investors.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.